Viatris Inc. (VTRS) Stock

Valuation data is not available for this stock.

With a beta of 0.92, Viatris Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 0.71 indicates the stock trades below its accounting value, which could signal value or distress.

Viatris Inc. achieves a profit margin of -24.60%, meaning it retains $-24.60 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 9.95% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -19.80% and ROA at 2.30%, the company achieves moderate returns on invested capital.

Viatris Inc.'s revenue declined by 5.70% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 70.60% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against DRUG MANUFACTURERS - SPECIALTY & GENERIC industry averages for proper context.

Viatris Inc. offers a dividend yield of 5.04%, paying $0.48 per share annually. This high yield exceeds 4%, significantly outperforming the S&P 500 average of 1.5-2% and most investment-grade bonds. For income-focused investors, this represents an attractive cash flow opportunity, though high yields sometimes signal market concerns about sustainability. To receive the next dividend, shares must be purchased before the ex-dividend date of Aug 22, 2025.

The dividend sustainability can be assessed through the payout ratio - Viatris Inc. pays $0.48 per share in dividends against earnings of -$2.96 per share, resulting in a payout ratio of -16.22%. This conservative payout below 30% indicates excellent dividend safety with substantial room for future increases. The company retains most earnings for growth while still rewarding shareholders. The next dividend payment is scheduled for Sep 15, 2025.

Viatris Inc. has a market capitalization of $11.2B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 1.17B shares outstanding, the company's ownership is widely distributed. As a participant in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry, it competes with other firms in this sector.

Viatris Inc.'s book value per share is $13.36, while the current stock price is $10.26, resulting in a price-to-book (P/B) ratio of 0.77. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As a common stock, this represents equity ownership with voting rights.

9 analysts cover VTRS with 33% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $11.43 implies 11.4% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:1 Strong Buy, 2 Buy, 5 Hold, 01 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.